Q4 2024 Solara Active Pharma Sciences Ltd Earnings Call Transcript
Key Points
- Solara Active Pharma Sciences Ltd (BOM:541540) achieved a significant improvement in gross margins, moving almost 10 percentage points closer to historical highs of around 50%-51%.
- The company reaffirmed its guidance for FY25, projecting revenue growth to approximately INR1,500 crore and an EBITDA run rate of around INR260 crore to INR290 crore.
- Solara Active Pharma Sciences Ltd (BOM:541540) is focused on improving its margin profile, quality of business, and sales discipline, which is expected to yield positive results in the upcoming quarters.
- The company announced a rights issue to support its balance sheet and significantly reduce debt, aiming for a strong balance sheet and free cash generation.
- Solara Active Pharma Sciences Ltd (BOM:541540) is adding new products and customers to its portfolio and working on a significant cost reduction program, which is expected to enhance profitability.
- The company had to take a provisioning of approximately INR120 crore of COVID inventory due to restricted freedom to operate post-pandemic.
- There was a delay in uploading the Q4 FY24 results due to technical issues, which could have impacted investor confidence.
- The sales ramp-up is taking longer than expected, which may affect short-term revenue growth.
- Solara Active Pharma Sciences Ltd (BOM:541540) had to defer several actions due to an unexpected FDA inspection of its Vizag plant, impacting operational timelines.
- The reported EBITDA for Q4 was only INR11 crore, significantly lower than the adjusted EBITDA of INR38 crore, indicating ongoing financial challenges.
Ladies and gentlemen, good day, and welcome to the Solara Active Pharma Science Limited Q4 FY24 earnings conference call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Abhishek. Thank you, and over to you, sir.
Thank you very much. A very good afternoon to all of you, and thank you for joining us today for Solara Active Pharma Sciences earnings conference call for the fourth quarter and full year ended financial year 2024.
Today, we have with us Arun, Solara's Founder; Poorvank Purohit, MD and CEO; and Arun Kumar Baskaran, CFO, to share the highlights of the business and financials for the quarter. I hope you've gone through our results release and quarterly investor presentation, which have been uploaded on our website as well as in stock exchange website. The transcript of this call will be available in a week's time on the company's website.
Please note that today's discussion may be forward-looking in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
